We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Salvarx Group Plc | LSE:SALV | London | Ordinary Share | IM00BZ4SS228 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.50 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
05/9/2018 15:39 | "Crazy low valuation".....well only if the science works. Otherwise it is worth £0..... | dexdringle | |
03/9/2018 10:44 | Crazy low valuation I still expect deal to be viewed positively in North America so the existing discount will simply become bigger and bigger | the stigologist | |
29/8/2018 00:35 | Update re proposed disposal and demerger Further to the announcement of 14 August 2018 relating to the proposed disposal of the Company's 94.2 per cent. interest in its subsidiary SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company has been informed that the Portage shareholder circular has now been submitted to the Canadian Securities Exchange ("CSE") for review. Following completion of the CSE review, both Portage and the Company will publish their respective shareholder circulars and a further announcement will be made by the Company. | the stigologist | |
27/8/2018 08:14 | If a startup company can be valued at $10 billion on just 40 patients data the potential for Intensity to be a $1 billion dollar company in the near future can't be dismissed. The Insiders clearly think we are onto something massive. | the stigologist | |
27/8/2018 08:12 | These are mind boggling numbers... " The investor community is also optimistic about this sector with record amounts of venture money flowing into startups this past year. In fact, in February 2018, BMS recorded the largest upfront payment for a license in history. They paid US$3.6 billion for 35% of the profits on Nektar's immunotherapy after seeing data on approximately 40 patients." | the stigologist | |
26/8/2018 11:46 | One does get the impression that ducks are being lined up in a row. Fig. | fig1 | |
26/8/2018 10:30 | Agree Stig. Intensity hasn’t tweeted since Dec 2017, now they tweet every day. Take the hint | jonesyboy 27 | |
26/8/2018 01:03 | In 5 years Intensity only ever tweeted 200 times up to August 20th (about 40 tweets a year, less than one a week) In the last week Intensity have tweeted about 10 tweets, including retweeting a tweet mentioning #SALV and they've hinted their next major Presentation of Data is due in October... The writing is pretty much on the wall for anybody with more than one braincell. SALV / Portage clean up September Intensity results October Intensity will be looking like a $1bn+ company SALV/Portage investors are going to clean up bigtime Mellon etc aren't in this for a minor £m here or there, they're going for the big one £100m+ | the stigologist | |
26/8/2018 00:31 | Great consolidation expect 100p+ soon | the stigologist | |
23/8/2018 09:34 | Jonesy, Thanks for confirming Portage will be under the complete control of Mellon and Bailey. The shell will be able to sell Portage to pay off debt, admin costs with a bit of cash left over. It will need to do an RTO within 12 months (6 months before suspension and then 6 months until the listing is cancelled). Unless Eke has something lined up, and he may have one of his own businesses, that is quite a racy timeline given all the bureaucracy involved. | sweet karolina | |
22/8/2018 17:14 | Mellon & Bailey hold 40% portage pre-deal and will hold ~60% of portage post deal. With the Salv shell waiting with 60 million + portage shares. What will they use the shell for is the question.... | jonesyboy 27 | |
22/8/2018 13:40 | Cudmore. Clown who posts on wrong thread. Filtered. | dexdringle | |
22/8/2018 12:43 | As I said earlier!! IIP! | cudmore | |
22/8/2018 08:53 | IIP about to take off. 30p short term easily here. | cudmore | |
22/8/2018 07:27 | That is the problem with many new drugs, they pass stage 1, which shows they do no harm, they many get part way through stage 2 showing some benefits, but when they go up against existing drugs they often fail to show a clear efficacy advantage. Even then commercial success is not guaranteed as it all depends on whether NHS / Insurance companies are prepared to pay the extra for them. It will be interesting to read the valuation report, which gives a range of values using a variety of techniques, ultimately though it is a lot like waiting to see if your numbers come up in the lottery. I expect the valuation report will be made available here: | sweet karolina | |
22/8/2018 07:18 | Also Dex, before we get ahead of ourselves, there is competition... https://dailym.ai/2B | fig1 | |
22/8/2018 06:59 | Good god. What did they say in the prior tweet that could possibly have left the door open to that interpretation such that a clarification was necessary ? Summary: Tweet one - good news a patient has survived six years using drugs Tweet two - just to be clear, they weren't our drugs, they were someone else's drugs that are clearly working thus rendering our drugs potentially redundant Great. Well done. | dexdringle | |
21/8/2018 21:20 | This is a nice story but I hope the person responsible for tweeting at Intensity leaves out the whimsy and sticks to facts pertaining to relevant trials. This is just damaging potentially. https://twitter.com/ | fig1 | |
21/8/2018 16:26 | About to take off soon. Doing a deal when it's quiet in August. Expect big news and interest during September. I can see Portage shares doing very well as those who benefited from the $200m+ pay out previously realise these guys are going for a repeat if not a bigger better deal having demonstrated their understanding of this sector before | the stigologist | |
21/8/2018 15:18 | Oh, there we go. Pressure building..... | fig1 | |
21/8/2018 07:52 | I look forward to your contribution to the discussion. It is clear that between Mellon and Bailey they will end up with total control of Portage post deal, it is good of you to crunch the figures to confirm that. At least you are beginning to realise that it is the ordinary PIs invested in Portage that are going to be the real deciders. Biohaven like deals come around once in a blue moon. Portage got a good deal when they bought into Biohaven ie they did not pay 5 times what another market thought it was worth. Some PIs will, as you say, blindly follow management. The independent valuation produces a range of valuations not a single definitive valuation as there is no way to value a company like SALV Ltd definitively. It will be interesting to read it when Portage publish it with the circular. Hopefully Portage will also give the detailed result of the vote, ie number of shares voted each way. If it is anything like UK votes only about 50% of those eligible to vote will vote. The 50% that do will care deeply enough one way or the other to act in the way PIs can if the vote does not go their way. The available data (perhaps you can find more) shows Portage is relatively illiquid and will therefore be significantly impacted by a relatively small number of shares traded. In your contribution to the discussion you might also want to consider why more SALV shares were sold than bought yesterday. | sweet karolina | |
21/8/2018 06:23 | Juvenescence doesn't currently have a market listing as far as I know. | fig1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions